Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603229 Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
82 GF Score
Price ¥8.10
GF Value ¥10.26
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Ausun Pharmaceutical Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zhejiang Ausun Pharmaceutical Co Valuation Rank Related Terms

SHSE:603229
82GF Score
Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.10 is trading 21.1% below its estimated GF Value™ of ¥10.26. GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603229:

  • Valuation Rank:
  • GF Value™: ¥10.26 vs. price of ¥8.10 (21.1% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Ausun Pharmaceutical Co Business Description

Address No.5, Donghai 4th Avenue, chemical raw materials base Linhai Park East, Zhejiang Province, Taizhou, CHN, 317016
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
82GF Score

Get the complete analysis for SHSE:603229

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.10
Price
¥10.26
GF Value